UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Scientific reports, 2024-07, Vol.14 (1), p.17515-12, Article 17515

2024

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.249-258

2012

Volltextzugriff (PDF)

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

Chest, 2013-12, Vol.144 (6), p.1795-1802

2013

Volltextzugriff (PDF)

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI

Chest, 2012-10, Vol.142 (4), p.685A-685B

2012

Volltextzugriff (PDF)

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Chest, 2010-01, Vol.137 (1), p.115-121

2010

Volltextzugriff (PDF)

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Chest, 2000-12, Vol.118 (6), p.1538-1546

2000

Volltextzugriff (PDF)

Mometasone furoate nasal spray : A review of safety and systemic effects

Drug safety, 2007-01, Vol.30 (4), p.317-326

2007

Volltextzugriff (PDF)

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.321-327

2006

Volltextzugriff (PDF)

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1501-1508

2012

Volltextzugriff (PDF)

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Journal of clinical pharmacology, 2013-05, Vol.53 (5), p.540-549

2013

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European journal of clinical pharmacology, 2012-07, Vol.68 (7), p.1049-1056

2012

Volltextzugriff (PDF)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

Clinical pharmacology in drug development, 2018-02, Vol.7 (2), p.143-150

2018

Volltextzugriff (PDF)

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Chest, 2007-10, Vol.132 (4), p.479A-479A

2007

Volltextzugriff (PDF)

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Clinical science (1979), 1996-09, Vol.91 (3), p.283-291

1996

Volltextzugriff (PDF)

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

International journal of clinical pharmacology and therapeutics, 2014-10, Vol.52 (10), p.889-899

2014

Volltextzugriff (PDF)

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1509-1516

2012

Volltextzugriff (PDF)

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.291-300

2012

Volltextzugriff (PDF)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease, 2013-01, Vol.8 (default), p.107-116

2013

Volltextzugriff (PDF)

Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial

Clinical pharmacology in drug development, 2014-01, Vol.3 (1), p.18-24

2014

Volltextzugriff (PDF)

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Clinical pharmacology in drug development, 2014-05, Vol.3 (3), p.229-234

2014

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Circulation (New York, N.Y.), 2001-07, Vol.104 (4), p.406-411

2001

Volltextzugriff (PDF)

Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers

Clinical pharmacology in drug development, 2013-07, Vol.2 (3), p.223-230

2013

Volltextzugriff (PDF)

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

Clinical pharmacology in drug development, 2015-01, Vol.4 (1), p.56-62

2015

Volltextzugriff (PDF)

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.90-98

2013

Volltextzugriff (PDF)

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects

Clinical pharmacology in drug development, 2013-10, Vol.2 (4), p.310-315

2013

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Infectious Diseases

ThemaAzetidines - Pharmacokinetics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Mometasone furoate nasal spray : A review of safety and systemic effects

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects

Aktive Filter

Suchergebnisse filtern